Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,182,830 papers from all fields of science
Search
Sign In
Create Free Account
100 ML Immunoglobulin G, Human 100 MG/ML Injection [Privigen]
Known as:
Privigen 10 GM per 100 ML Injection
, privigen 10 % in 100 ML Injection
, Human Immunoglobulin G 10 g in 100 mL INTRAVENOUS LIQUID [Privigen]
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Albumin Human, USP
Immunoglobulin A, Human
Immunoglobulin G, Human
Injection
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pharmacokinetic properties of Privigen® in Japanese patients with primary immunodeficiency
T. Morio
,
G. Baheti
,
M. Tortorici
,
J. Hofmann
,
M. Rojavin
Immunological Medicine
2019
Corpus ID: 209408730
Abstract This prospective, Phase 3, open-label, study (EudraCT: 2016-001631-12) evaluated pharmacokinetic (PK) characteristics of…
Expand
2017
2017
Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
D. Suez
,
M. Stein
,
+10 authors
L. Yel
Journal of Clinical Immunology
2017
Corpus ID: 1256407
Author(s): Suez, Daniel; Stein, Mark; Gupta, Sudhir; Hussain, Iftikhar; Melamed, Isaac; Paris, Kenneth; Darter, Amy; Bourgeois…
Expand
2017
2017
High-resolution physicochemical characterization of different intravenous immunoglobulin products
N. Washburn
,
Robin Meccariello
,
+9 authors
C. Bosques
PLoS ONE
2017
Corpus ID: 41719766
Intravenous immunoglobulin (IVIg) is a complex mixture drug comprising diverse immunoglobulins and non–IgG proteins purified from…
Expand
2016
2016
Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment
Simon S. Gerber
,
Annette Gaida
,
+6 authors
M. Imboden
BioDrugs
2016
Corpus ID: 6917082
Hemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with the…
Expand
2014
2014
A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
J. Lozano‐Blasco
,
M. Martín-Mateos
,
+5 authors
A. Plaza
Allergologia et Immunopathologia
2014
Corpus ID: 37045665
Highly Cited
2013
Highly Cited
2013
Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
J. Léger
,
J. D. De Bleecker
,
+10 authors
I. Merkies
Journal of the peripheral nervous system
2013
Corpus ID: 17631093
This prospective, multicenter, single‐arm, open‐label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10…
Expand
Highly Cited
2012
Highly Cited
2012
Treatment of multiple system atrophy using intravenous immunoglobulin
P. Novak
,
Arlene Williams
,
P. Ravin
,
Omar Zurkiya
,
A. Abduljalil
,
V. Novak
BMC Neurology
2012
Corpus ID: 1830894
BackgroundMultiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as…
Expand
2011
2011
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.
M. Berger
Immunotherapy
2011
Corpus ID: 31651592
Liquid IgG preparations are preferred over lyophilized preparations because reconstitution is not required. Formation of dimers…
Expand
2010
2010
Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion Rates
J. Sleasman
,
C. Duff
,
T. Dunaway
,
M. Rojavin
,
M. Stein
Journal of Clinical Immunology
2010
Corpus ID: 2636759
PurposeThe tolerability of L-proline-stabilized Privigen®, a new 10% liquid immunoglobulin for intravenous administration, was…
Expand
2009
2009
Efficacy and safety of privigen in children and adolescents with primary immunodeficiency.
J. Church
,
M. Borte
,
+6 authors
P. Kiessling
2009
Corpus ID: 72288178
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE